NHS: Drugs

Serious Shortage Protocols (SSPs) enable community pharmacists to supply a specified medicine or device in accordance with a protocol rather than a prescription, with the patient’s consent, and without needing to seek authorisation from the prescriber. SSPs are additional tools that have been used in recent years, alongside a range of other mechanisms, to manage and mitigate medicine and medical devices shortages. SSPs are not introduced unless sufficient supplies of the alternative product to be supplied in accordance with the SSP are available to support the market.

Furthermore, SSPs are not suitable for all medicines and patients. For example, patients with complex health needs may not be considered suitable for a supply in accordance with an SSP. In these cases, patients would always be referred back to the prescriber for any decision about their treatment before any therapeutic or generic alterative is supplied. SSPs are not issued for controlled drugs in Schedule II, such as methylphenidate, except under very restricted circumstances.

The Department is aware of a supply issue affecting methylphenidate prolonged-release tablets. These supply issues are taking longer to resolve than the Department originally anticipated, and the Department is working with the respective suppliers to further improve the United Kingdom’s supply for the short and long-term as soon as possible. There are no plans to issue a SSP for methylphenidate.

The Department is currently unaware of any medicine supply issues affecting dexamfetamine, atomoxetine, lisdexamfetamine, guanfacine, oestrogel, bupropionand, lamotrigine. Therefore, there are no plans to issue SSPs for these medicines.